Product and Pipeline Analysis of the Global Colorectal Cancer Market

Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level

USD 3,950

* Required Fields

USD 3,950

PAY BY INVOICE

Be the first to review this product

Research Overview


This Frost & Sullivan research service on the global colorectal cancer market provides in-depth analyses of industry trends, market shares, competitive analysis, market opportunities and revenue forecasts from 2014 to 2021. It also features a SWOT analysis of drugs that are available in the market as well as those under development. In this market research, Frost & Sullivan's expert analysts thoroughly examine the following modalities:



  • targeted therapies

  • cytotoxics

  • cancer vaccines

  • other products (bone calcium regulators, cytotoxic antibiotics, anti-cancer agents, immunostimulants, alkylating agents and anti-metabolites).


The evaluation of each drug class is supported by information on clinical trials, projected launch timelines, and epidemiology.


Market Overview


Strong drug pipeline continues to expand


The pipeline for colorectal cancer treatment boasts a vast number and variety of remedies. The high incidence of the disease, unmet treatment needs and their commercial potential attracts drug developers to the market. Advancements are centred on identifying new molecular targets and reducing toxicity. Several immunotherapies and cancer vaccines are being developed as pharmaceutical and biotech companies attempt to utilise the body's own immune system mechanism to attack tumours. Immune-based therapies will play a vital role in future cancer treatment as they can increase survival rates and overcome patients' resistance to existing therapeutics.


Colorectal cancer care edges toward personalisation


With the increasing focus on treatment outcomes, the market for colorectal cancer is undoubtedly moving toward personalised modes of care. Targeted solutions dominate the colorectal cancer pipeline, accounting for 60 percent of the treatment modalities under production. The improved understanding of the molecular mechanisms of colorectal cancer will facilitate the identification of newer targets and give rise to multi-targeted therapies. Meanwhile, biomarker testing is expected to become the standard of care, as it can help select a targeted therapy for a patient's particular need (predictive biomarkers), as well as define the patient's specific tumour type (prognostic biomarkers).


Beyond effective care delivery, employing targeted solutions will greatly enhance the reimbursement potential. By treating patients that are most likely to respond to a particular therapy, healthcare givers will be able to better justify the high costs to insurance firms and government payers. Therefore, clinical trials of targeted therapy drugs using biomarkers as surrogate endpoints will boost their chances of approval. Ultimately, the use of targeted remedies, coupled with immunotherapy, though complicated, will bridge the gap between the current need and future scope of colorectal cancer treatment globally.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued)Executive Summary (continued)Executive Summary (continued)Executive Summary (continued)Physician Treatment Guidelines—Lines of TherapyKey TrendsMarket Opportunities Companies to WatchMethodology and ScopeMethodology and ScopeMarket OverviewMarket Overview—Types of Treatment in DevelopmentMarket Overview—Global Incidences of CRCMarket Overview—US Incidence Rates by Year and SexMarket Overview—Biomarker Type SegmentationMarket Overview—Key Mergers, Acquisitions, and PartnershipsMarket Overview—Recent DevelopmentsRevenue Forecast Global CRC Market—Revenue ForecastRevenue Forecast DiscussionRevenue Forecast Discussion (continued)Revenue Forecast Discussion (continued)Competitive LandscapeCompetitive Landscape OverviewCompetitive Landscape—Phase III to LaunchCompetitive Landscape—Phase IICompetitive Landscape—Phase IMarketed ProductsKey Marketed ProductsKey Marketed Products (continued)Key Marketed Products (continued)Key Marketed Products (continued)Pipeline Drugs AnalysisPipeline Synopsis—Phase IIIPipeline Synopsis—Phase III (continued)Pipeline Synopsis—Phase III (continued)Pipeline Synopsis—Phase III (continued)Pipeline Synopsis—Phase III (continued)Pipeline Synopsis—Phase IIPipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase II (continued)Pipeline Synopsis—Phase I Pipeline Synopsis—Phase I (continued)Pipeline Synopsis—Phase I (continued)Pipeline Synopsis—Phase I (continued)Pipeline Synopsis—Phase I (continued)Pipeline Synopsis—Phase I (continued)Competitive Landscape—Pivotal Phase III TrialsTimeline of Key EventsPatent ExpirationsPipeline DiscussionPipeline Discussion (continued)Product Dashboard of Recently Approved Drugs and Late-stage Pipeline Drug CandidatesProduct Dashboard: Avastin (Bevacizumab)—Genentech Inc. (Roche Group)Avastin (Genentech, Roche)—SWOT AnalysisProduct Dashboard—BBI503: Boston BiomedicalBBI503 (Boston Biomedical)—SWOT AnalysisProduct Dashboard—Cyramza (ramicirumab): Eli LillyCyramza (ramicirumab) (Eli Lilly)—SWOT AnalysisProduct Dashboard—Erbitux (cetuximab): Eli Lilly/BMS/MerckErbitux (Eli Lilly, BMS, and Merck)—SWOT AnalysisProduct Dashboard—Imprime PGG: BiotheraImprime PGG (Biothera)—SWOT AnalysisProduct Dashboard—Lonsurf (TAS-102): Taiho (Otsuka)Lonsurf (TAS–102) (Taiho, Otsuka)—SWOT AnalysisProduct Dashboard—MGN1703: MologenMGN1703 (Mologen)—SWOT AnalysisProduct Dashboard—Nintedanib (BIBF-1120, OFEV): Boehringer IngelheimNintedanib (BIBF–1120, OFEV) (BI)—SWOT AnalysisProduct Dashboard—Stivarga (regorafenib): Bayer/Onyx PharmaceuticalsStivarga (Bayer, Onyx)—SWOT AnalysisProduct Dashboard—Zaltrap (aflibercept): SanofiZaltrap (aflibercept) (Sanofi)—SWOT AnalysisConclusionsConclusionsConclusions (continued)The Last Word—3 Big PredictionsThe Last Word—DiscussionLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Related Research

Release Date : 20-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.